|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 233.5 USD | +1.56% |
|
+2.48% | -1.24% |
Charles River Laboratories International, Inc. revises earnings guidance for 2022. The Company is updating its 2022 financial guidance, which was previously provided on February 16, 2022. The company expects revenue growth to be 13.5% – 15.5% as compared to previous guidance of 13.0% – 15.0%.
GAAP EPS to be $8.70 – $8.95 as compared to previous guidance of $9.20 – $9.45.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.24% | 11.8B | |
| +25.69% | 48.09B | |
| +46.90% | 40.62B | |
| -3.46% | 40.43B | |
| -6.20% | 28.36B | |
| +9.17% | 24.89B | |
| -20.42% | 19.01B | |
| +28.07% | 12.09B | |
| +0.17% | 11.88B | |
| +19.33% | 11.45B |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 
